Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy

被引：3
|
作者：
RN Zárate R [1 ]
F Arias [2 ]
E Bandres [1 ]
E Cubedo [1 ]
R Malumbres [1 ]
J García-Foncillas [1 ]
机构：
[1] Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, 36 Pio XII Ave, Pamplona 31008, Spain
[2] Navarra Hospital center, s/n Irunlarrea Street, Pamplona 31008, Spain
来源：
World Journal of Gastroenterology | 2006年 / 37期
关键词：
Xeroderma pigmentosum group D gene; Polymorphism; Gastric cancer; Radiotherapy;
D O I：
暂无
中图分类号：
R735.2 [胃肿瘤];
学科分类号：
100214 ;
摘要：
AIM: To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer. METHODS: We used PCR-RFLP to evaluate the genetic XPD Lys751Gln polymorphisms in 44 patients with stage Ⅲ (48%) and Ⅳ (20%) gastric cancer treated with surgery following radiation therapy plus 5-fluorouracil/ leucovorin based chemotherapy. RESULTS: Statistical analysis showed that 75% (12 of 16) of relapse patients showed Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism was an independent predictor of high-risk relapse-free survival from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P = 0.036) and Kaplan-Meir test (P = 0.027, log-rank test). CONCLUSION: XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to chemo-radiotherapy in resected gastric cancer patients.
引用
收藏
页码：6032 / 6036
页数：5
相关论文
共 28 条
  • [21] Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: A systematic review and meta-analysis
    Ma, Qingtong
    Qi, Can
    Tie, Chong
    Guo, Zhanjun
    GENE, 2013, 530 (02) : 309 - 314
  • [22] ROLE OF RECTAL PROGNOSTIC INDEX (RPI) AS POTENTIAL PREDICTIVE FACTOR OF RECURRENCE IN PATIENTS WITH LOCAL ADVANCED RECTAL ADENOCARCINOMA TREATED WITH NEOADJUVANT CHEMO-RADIOTHERAPY (NEOCH-RT)
    Viudez, A.
    Sales, R.
    Rossini, A.
    Montserrat, A.
    Neus, G.
    Blazquez, S.
    Esteller, L.
    Perez, C.
    Pamies, J.
    Pelegri, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 110 - 110
  • [23] Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin
    DiPastena, F.
    Pond, G.
    Ahmadi, E.
    Tsakiridis, E. E.
    Steinberg, G. R.
    Tsakiridis, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E14 - E15
  • [24] Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients
    Ludovini, Vienna
    Floriani, Irene
    Pistola, Lorenza
    Minotti, Vincenzo
    Meacci, Marialuisa
    Chiari, Rita
    Garavaglia, Daniela
    Tofanetti, Francesca Romana
    Flacco, Antonella
    Siggillino, Annamaria
    Baldelli, Elisa
    Tonato, Maurizio
    Crino, Lucio
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2018 - 2026
  • [25] Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients
    Wang, Lei
    Wang, Le-Le
    Shang, Di
    Yin, Sheng-Jie
    Sun, Li-Li
    Wang, Xiao-Ying
    Ji, Hong-Bo
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2019, 35 (01): : 39 - 48
  • [26] Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine
    Zhou, M.
    Ding, Y. J.
    Feng, Y.
    Zhang, Q. R.
    Xiang, Y.
    Wan, H. Y.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) : 3310 - 3318
  • [27] The XPD lys751gln polymorphism in colorectal cancer patients treated in first line chemotherapy with 5-FU-oxaliplatin or 5-FU-irinotecan combinations:: a prognostic factor or a predictive marker of oxaliplatin efficiency?
    Le Morvan, V.
    Smith, D.
    Bellott, R.
    Brouste, V.
    Soubeyran, I.
    Rullier, A.
    Belleannee, G.
    Robert, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 48 - 48
  • [28] Correlation of cytidine deaminase (CDA), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing 1 (ERCC1) genes single nucleotide polymorphisms (SNPS) with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer (NSCLC) patients
    Tibaldi, Carmelo
    Giovannetti, Elisa
    Vasile, Enrico
    Mey, Valentina
    Nannizzi, Sara
    Lo Dico, Monica
    Orlandini, Cinzia
    Del Tacca, Mario
    Falcone, Alfredo
    Danesi, Romano
    ANNALS OF ONCOLOGY, 2007, 18 : 33 - 33
123